These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15080094)

  • 1. EU issues warning about HAART regimen.
    AIDS Patient Care STDS; 2004 Jan; 18(1):56-7. PubMed ID: 15080094
    [No Abstract]   [Full Text] [Related]  

  • 2. Warning issued on non-response rates.
    AIDS Patient Care STDS; 2003 Oct; 17(10):539. PubMed ID: 14588094
    [No Abstract]   [Full Text] [Related]  

  • 3. Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
    Silkiss RZ; Lee H; Gills Ray VL
    Arch Ophthalmol; 2009 Mar; 127(3):345-6. PubMed ID: 19273808
    [No Abstract]   [Full Text] [Related]  

  • 4. The continuing evolution of HIV therapy.
    Boyle BA
    AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603
    [No Abstract]   [Full Text] [Related]  

  • 7. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
    Delaugerre C; Roudiere L; Peytavin G; Rouzioux C; Viard JP; Chaix ML
    J Clin Virol; 2005 Mar; 32(3):241-4. PubMed ID: 15722030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected drug interactions and adverse events with antiretroviral drugs.
    Moyle G; Boffito M
    Lancet; 2004 Jul 3-9; 364(9428):8-10. PubMed ID: 15234836
    [No Abstract]   [Full Text] [Related]  

  • 10. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 11. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
    Callens S; De Schacht C; Huyst V; Colebunders R
    J Infect; 2003 Aug; 47(2):188-9. PubMed ID: 12860159
    [No Abstract]   [Full Text] [Related]  

  • 12. [Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():62-4. PubMed ID: 12043078
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
    Maserati R; De Silvestri A; Uglietti A; Colao G; Di Biagio A; Bruzzone B; Di Pietro M; Re MC; Tinelli C; Zazzi M;
    AIDS; 2010 Apr; 24(7):1013-8. PubMed ID: 20124969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Simply convincing. New fixed combination for HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():20-3. PubMed ID: 16385865
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute tubular necrosis in a patient receiving tenofovir.
    Lee JC; Marosok RD
    AIDS; 2003 Nov; 17(17):2543-4. PubMed ID: 14600530
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
    Ripamonti D; Maggiolo F; Suter F
    AIDS; 2007 May; 21(8):1059-60. PubMed ID: 17457107
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenofovir-related nephrotoxicity in HIV-infected patients.
    Barrios A; García-Benayas T; González-Lahoz J; Soriano V
    AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
    [No Abstract]   [Full Text] [Related]  

  • 18. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.
    Murphy MD; O'Hearn M; Chou S
    Clin Infect Dis; 2003 Apr; 36(8):1082-5. PubMed ID: 12684925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early nonresponse for tenofovir regimen.
    AIDS Patient Care STDS; 2003 Nov; 17(11):603. PubMed ID: 14748354
    [No Abstract]   [Full Text] [Related]  

  • 20. [Once daily administration improves therapy adherence in HAART. New substance class with more powerful reserves against virus resistance].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():86-9. PubMed ID: 11373792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.